CCR8 and neoplasm: Treatment of tumor bearing mice with the anti-CCR8 antibody was highly specific to tumor infiltrating Tregs, sparing both intratumoral effector T cells and Tregs in non-tumor tissues and ultimately enabling effective and long-lasting antitumor immunity (Campbell et al., 2021).